
Opinion|Videos|August 8, 2024
Key Unmet Needs Associated with Idiopathic and Progressive Pulmonary Fibrosis
Author(s)Paul Frohna, MD, PhD
Dr. Frohna covers unmet needs in the latest treatment guidelines and therapies used to combat idiopathic and progressive pulmonary fibrosis.
Advertisement
- What were the key updates for treatment in the 2022 ATS Guidelines and what additional information is needed in future iterations?
- How do you see the guidelines changing as novel agents enter the treatment landscape?
- There were no FDA-approved therapies for IPF/PPF prior to anti-fibrotic agents. How have these therapy options altered treatment of the disease?
Advertisement
Related to this article

Blood RNA risk score from 31 small RNAs flags Lung Cancer in smokers up to 10 years early, potentially guiding earlier LDCT screening.

The CEO and founder of a digital behavior company has advice for health plans considering asynchronous behavioral health services like those that his company provides.

In this interview, Melody Chang, RPh, BCOP, MBA, vice president of pharmacy operation at the American Oncology Network, discusses the network's pharmacy strategy and priorities.

The purchase comes as the "big 3" drug wholesalers are coming under scrutiny for their market dominance and the possible perils of vertical integration.

In this discussion, Heather Burrell-Ward, M.D., provides an overview of her recent study that found TMS aimed at the default mode network improved processing speed in schizophrenia.

Rand researchers identify standardizing supplemental benefits, limiting the number of plans an insurer can market and reforming broker commissions as policy proposals that would benefit beneficiaries while not harming the government or the plans.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
McKesson, private equity firm buy home infusion company, Option Care Health
2
Medical debt burdens more than 1 in 4 adults in the U.S., survey finds
3
Medicare Advantage needs fixing. Here are 3 feasible repairs
4
Christine Johnston on why biosimilars are losing formulary ground
5






